Anatomic Pathology Market Size, Share & Industry Analysis By Product (Instruments {Automatic Stainers, Tissue Processors, Microtomes & Cryostat, and Others} and Consumables & Reagents), By Application (Diagnosis {Cancer, Autoimmune Diseases, Infectious Diseases, and Others}, and Research), By End-user (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034

The global anatomic pathology market is experiencing significant growth, primarily driven by the growing use of molecular pathology, IHC, and in situ hybridization (ISH) to guide targeted therapies. As a result, the pharmaceutical & biotechnology companies are relying on anatomic pathology to validate biomarkers and stratify patients in oncology and immunotherapy trials.

Moreover, the integration of companion diagnostics with tissue testing is expected to spur market expansion further. Additionally, academic & research institutes are expanding pathology education and translational research, which is expected to drive the utilization of instruments.

Anatomic Pathology Market Driver

Rising Incidence of Cancer to Fuel Market Growth

Over the past few years, the increasing incidence of cancer has driven the demand for anatomic pathology instruments and consumables. Cancer diagnosis is heavily dependent on tissue-based histopathological examination, which is spurring the demand for biopsy testing, immunohistochemistry (IHC), and molecular pathology. Moreover, the growing number of cancer screening initiatives and the adoption of personalized treatment plans are expected to increase the utilization of anatomic pathology solutions further, thereby driving market growth.

• For instance, according to data published by the Global Cancer Statistics 2022, an estimated 20.0 million new cancer cases occurred in 2022.

Download Free sample to learn more about this report.

According to data published by Global Cancer Statistics 2022, lung cancer accounted for the largest number of new cancer cases (2,480,301) in 2022, followed by breast cancer.

Anatomic Pathology Market Restraint

Shortage of Skilled Pathologists to Hamper Market Growth

The shortage of skilled pathologists remains a critical barrier to the widespread utilization of advanced instruments. Despite increasing testing volumes, this limited availability is leading to longer turnaround times and diagnostic backlogs, which in turn are constraining the adoption of advanced tools. Additionally, the high cost of training and retaining skilled personnel is posing further challenges for laboratories.

• For instance, according to data from the World Health Organization (WHO) in 2021, the world faces a shortage of approximately four times fewer pathologists than are required globally. The deficit is moderate in Europe, severe across Asia, and particularly critical in Africa.

Anatomic Pathology Market Opportunity

Growth of Digital and AI-Based Pathology to Offer Lucrative Opportunities

In recent years, the shift toward digital pathology and AI-driven diagnostic interpretation is expected to present lucrative growth opportunities for market expansion. Digital slide scanners, image analysis software, and telepathology platforms have enabled remote collaboration, faster case reviews, and improved accuracy. Additionally, AI algorithms assist in early cancer detection, biomarker quantification, and standardized reporting, thereby enhancing productivity in high-volume labs. Furthermore, its integration with hospital information systems is expected to support workflow automation.

• For instance, in February 2024, F. Hoffmann-La Roche Ltd entered into an exclusive collaboration agreement with PathAI to develop AI-powered digital pathology algorithms for Roche Tissue Diagnostics’ companion diagnostics business, integrating these algorithms into Roche’s Navify Digital Pathology platform worldwide.

Segmentation

Key Insights

The report covers the following key insights:

• Research & Development Expenditure, By Key Countries/Region, 2024
• Technological Advancements in Anatomic Pathology
• Key Industry Developments (Mergers, Acquisitions & Partnerships, and Others)

Analysis by Product

Based on product, the market is bifurcated into instruments and consumables & reagents.

The consumables segment held the largest share in 2024. High usage frequency, recurring replacement needs, and increasing test volumes in oncology and infectious disease diagnostics primarily drive the growth. Moreover, the increased automation is also driving the ready-to-use reagent kits compatible with automated systems.

Analysis by Application

By application, the market is subdivided into diagnosis {cancer, autoimmune diseases, infectious diseases, and others}, and research.

The diagnosis segment is expected to hold a major share during the forecast period. The growth is driven by rising biopsy volumes and increasing use of tissue-based molecular diagnostics and immunohistochemistry, as anatomic pathology plays a crucial role in tumor classification and treatment decision-making.

Analysis by End-user

The market, by end-user, is categorized into hospitals, diagnostic laboratories, academic & research institutes, and others.

The hospitals segment held the largest market share in 2024. The majority of laboratory tests are performed in hospital-based laboratories due to better accessibility, reduced turnaround time, and other factors. As a result, the key players are increasing product supply to these settings, which is expected to contribute to the segment’s growth.

• For instance

Regional Analysis

Request for Customization   to gain extensive market insights.

On the basis of region, the market has been analyzed across North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa.

North America held the largest share of the global anatomic pathology market in 2024. The growth is attributed to the well-established healthcare infrastructure, including hospital-based and stand-alone laboratories, which contributes to the higher utilization of advanced anatomic pathology instruments in the U.S. and Canada. Moreover, the presence of established players in the region is also ensuring the strong availability of advanced instruments.

• For instance, as of November 2025, according to data from Laboratory of Florida LLC, there were around 8,650 hospital-based labs and 5,414 independent labs in the U.S.

Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period. The region’s growth is driven by significant patient volumes in countries such as China and India, which in turn is expected to drive the demand for laboratory diagnosis. Moreover, key players are expanding their presence in this region with new facilities, driven by the rising demand for research applications in countries such as South Korea, Australia, Japan, and China, which in turn is increasing the utilization of anatomic pathology instruments.

Key Players Covered

Major players, including Danaher, PHC Holdings Corporation, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, and F. Hoffmann-La Roche Ltd, dominate the global anatomic pathology market. These players have a significant portfolio of instruments and reagents. Further, they are expanding into emerging countries to enhance their market reach.

The report includes the profiles of the following key players:

• Danaher (U.S.)
• PHC Holdings Corporation (Japan)
• Quest Diagnostics Incorporated (U.S.)
• Laboratory Corporation of America Holdings (U.S.)
• Hoffmann-La Roche Ltd (Switzerland)
• Agilent Technologies, Inc. (U.S.)
• Sakura Finetek USA, Inc. (U.S.)
• NeoGenomics Laboratories. (U.S.)
• BioGenex (U.S.)
• Bio SB (U.S.)

Key Industry Developments

• December 2024: Proteocyte AI and StrataDx entered into a strategic partnership to expand U.S. market access for Straticyte. This advanced prognostic test predicts oral cancer risk, with StrataDx providing additional laboratory capacity.
• March 2023: PathAI announced the early adoption of its AISight digital pathology platform and AIM-PD-L1 NSCLC RUO algorithm by 13 leading anatomic pathology laboratories across the U.S., advancing precision medicine through AI-driven research.